Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C26H28N6O.ClH |
| Molecular Weight | 477.001 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)N1CCN(CC2=CN=C(O2)C3=CC(=CC4=C3C=NN4)C5=CC=CC6=C5C=CN6)CC1
InChI
InChIKey=GECUEJGEJLAXQA-UHFFFAOYSA-N
InChI=1S/C26H28N6O.ClH/c1-17(2)32-10-8-31(9-11-32)16-19-14-28-26(33-19)22-12-18(13-25-23(22)15-29-30-25)20-4-3-5-24-21(20)6-7-27-24;/h3-7,12-15,17,27H,8-11,16H2,1-2H3,(H,29,30);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C26H28N6O |
| Molecular Weight | 440.5401 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
GSK-2269557 (nemiralisib), a PI3Kδ inhibitor, is in development as an anti-inflammatory drug for the treatment of inflammatory airways disease. Studies in moderate or severe stable COPD patients have shown an acceptable safety and tolerability profile when GSK-2269557 was administered via inhalation. Cough was the most commonly reported adverse event.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:51:28 UTC 2023
by
admin
on
Sat Dec 16 11:51:28 UTC 2023
|
| Record UNII |
II4WQU7U3O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1254036-77-5
Created by
admin on Sat Dec 16 11:51:28 UTC 2023 , Edited by admin on Sat Dec 16 11:51:28 UTC 2023
|
PRIMARY | |||
|
GSK-2269557
Created by
admin on Sat Dec 16 11:51:28 UTC 2023 , Edited by admin on Sat Dec 16 11:51:28 UTC 2023
|
PRIMARY | MedKoo CAT NO: 522375CAS NO: 1254036-77-5(HCl salt), 1254036-71-9(free base)Description: GSK-2269557 is a potent and selective PI3K.DELTA. inhibitor. GSK-2269557 is is currently in clinical trials for the treatment of respiratory diseases such as asthma and COPD. GSK-2269557 is highly selective for PI3K.DELTA. over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation. PI3K.DELTA. is highly enriched in leukocytes, making it an attractive target for the treatment of inflammatory conditions, such as asthma,6 chronic obstructive pulmonary disease (COPD), and autoimmune diseases. (last updated: 9/3/2015). | ||
|
CHEMBL3545250
Created by
admin on Sat Dec 16 11:51:28 UTC 2023 , Edited by admin on Sat Dec 16 11:51:28 UTC 2023
|
PRIMARY | |||
|
100000175665
Created by
admin on Sat Dec 16 11:51:28 UTC 2023 , Edited by admin on Sat Dec 16 11:51:28 UTC 2023
|
PRIMARY | |||
|
II4WQU7U3O
Created by
admin on Sat Dec 16 11:51:28 UTC 2023 , Edited by admin on Sat Dec 16 11:51:28 UTC 2023
|
PRIMARY | |||
|
49784084
Created by
admin on Sat Dec 16 11:51:28 UTC 2023 , Edited by admin on Sat Dec 16 11:51:28 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Drug: GSK 2269557(Primary); Indication: Asthma; Focus: Therapeutic Use; Sponsor: GlaxoSmithKline; Most Recent Events: 25 Mar 2016 Last checked against European Clinical Trials Database record, 01 Dec 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov, 05 Aug 2015 New trial record
|